Indexed in Journament

hematological oncology

ISSN 1099-1069· EN

Certificate of Indexing
Login or register to claim ownership or editorship of this journal.
39.3/100
Journament Score
#9,452
Journament Rank
6
Articles Indexed

About This Journal

Short Name hematol oncol
Abbreviated Name hematol oncol
ISSN 1099-1069

Indexings

ncbi ulakbim sci

Tools & Certificate of Indexing

Certificate of Indexing
Quality Badge Widget - Embed on Your Website

Display your journal's verified indexing scores on your website with our self-contained widget.

One-Line JavaScript Embed:
Advantages: Single-line script, seamless DOM integration, clickable badges linking to full journal profile.
Standard iFrame Embed Code:
Widget Preview:

Publications Per Year

Articles (6)

2019
STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in Primary Central Nervous System Lymphoma.
Mondello, Patrizia;Cuzzocrea, Salvatore;Arrigo, Carmela;Pitini, Vincenzo;Mian, Michael;Bertoni, Francesco;
376 views DOI Abstract
2019
Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach.
Iurlo, Alessandra;Elli, Elena Maria;Palandri, Francesca;Cattaneo, Daniele;Bossi, Anna;Cortinovis, Ivan;Bucelli, Cristina;Orofino, Nicola;Brioschi, Filippo;Auteri, Giuseppe;Bianchi, Paola;Fabris, Sonia;Isimbaldi, Giuseppe;Sabattini, Elena;Baldini, Luca;Gianelli, Umberto;
Vol. 37 , No. 4 , pp. 424-433
333 views DOI Abstract
2019
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.
Andriani, Alessandro;Elli, Elena;Trapè, Giulio;Villivà, Nicoletta;Fianchi, Luana;Di Veroli, Ambra;Niscola, Pasquale;Centra, Antonia;Anaclerico, Barbara;Montanaro, Guido;Martini, Vincenza;Aroldi, Andrea;Carmosino, Ida;Voso, Maria Teresa;Breccia, Massimo;Montanaro, Marco;Foà, Roberto;Latagliata, Roberto;
Vol. 37 , No. 3 , pp. 291-295
326 views DOI Abstract
2020
Low incidence of post-transplant lymphoproliferative disorder after allogeneic stem cell transplantation in patients with lymphoma treated with rituximab.
Fujimoto, Ayumi;Hiramoto, Nobuhiro;Yamasaki, Satoshi;Inamoto, Yoshihiro;Ogata, Masao;Sugio, Yasuhiro;Fukuda, Takahiro;Uchida, Naoyuki;Ikegame, Kazuhiro;Matsuoka, Ken-Ichi;Shiratori, Souichi;Kondo, Tadakazu;Miyamoto, Toshihiro;Eto, Tetsuya;Ichinohe, Tatsuo;Kanda, Yoshinobu;Atsuta, Yoshiko;Suzuki, Ritsuro;, ;
319 views DOI Abstract
2019
The lenalidomide/bortezomib/dexamethasone regimen for the treatment of blastic plasmacytoid dendritic cell neoplasm.
Marmouset, Vincent;Joris, Magalie;Merlusca, Lavinia;Beaumont, Marie;Charbonnier, Amandine;Marolleau, Jean-Pierre;Gruson, Bérengère;
276 views DOI Abstract
2025
Efficacy of Axicabtagene Ciloleucel Compared to Historical Treatments for Relapsed/Refractory Diffuse Large B-Cell Lymphoma of Asian Descent: A Matching Adjusted Indirect Comparison of ZUMA-1 vs REAL-TREND.
Locke, Frederick L; Ball, Graeme; Ray, Markqayne D; Li, Tony; Limbrick-Oldfield, Eve H; Popoff, Evan; Kanters, Steve
Vol. 43 , pp. e70100
86 views DOI Abstract
2025
Efficacy of Axicabtagene Ciloleucel Compared to Historical Treatments for Relapsed/Refractory Diffuse Large B-Cell Lymphoma of Asian Descent: A Matching Adjusted Indirect Comparison of ZUMA-1 vs REAL-TREND.
Locke, Frederick L; Ball, Graeme; Ray, Markqayne D; Li, Tony; Limbrick-Oldfield, Eve H; Popoff, Evan; Kanters, Steve
Vol. 43 , pp. e70100
86 views DOI Abstract
2020
Low incidence of post-transplant lymphoproliferative disorder after allogeneic stem cell transplantation in patients with lymphoma treated with rituximab.
Fujimoto, Ayumi;Hiramoto, Nobuhiro;Yamasaki, Satoshi;Inamoto, Yoshihiro;Ogata, Masao;Sugio, Yasuhiro;Fukuda, Takahiro;Uchida, Naoyuki;Ikegame, Kazuhiro;Matsuoka, Ken-Ichi;Shiratori, Souichi;Kondo, Tadakazu;Miyamoto, Toshihiro;Eto, Tetsuya;Ichinohe, Tatsuo;Kanda, Yoshinobu;Atsuta, Yoshiko;Suzuki, Ritsuro;, ;
319 views DOI Abstract
2019
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.
Andriani, Alessandro;Elli, Elena;Trapè, Giulio;Villivà, Nicoletta;Fianchi, Luana;Di Veroli, Ambra;Niscola, Pasquale;Centra, Antonia;Anaclerico, Barbara;Montanaro, Guido;Martini, Vincenza;Aroldi, Andrea;Carmosino, Ida;Voso, Maria Teresa;Breccia, Massimo;Montanaro, Marco;Foà, Roberto;Latagliata, Roberto;
Vol. 37 , No. 3 , pp. 291-295
326 views DOI Abstract
2019
Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach.
Iurlo, Alessandra;Elli, Elena Maria;Palandri, Francesca;Cattaneo, Daniele;Bossi, Anna;Cortinovis, Ivan;Bucelli, Cristina;Orofino, Nicola;Brioschi, Filippo;Auteri, Giuseppe;Bianchi, Paola;Fabris, Sonia;Isimbaldi, Giuseppe;Sabattini, Elena;Baldini, Luca;Gianelli, Umberto;
Vol. 37 , No. 4 , pp. 424-433
333 views DOI Abstract
2019
STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in Primary Central Nervous System Lymphoma.
Mondello, Patrizia;Cuzzocrea, Salvatore;Arrigo, Carmela;Pitini, Vincenzo;Mian, Michael;Bertoni, Francesco;
376 views DOI Abstract
2019
The lenalidomide/bortezomib/dexamethasone regimen for the treatment of blastic plasmacytoid dendritic cell neoplasm.
Marmouset, Vincent;Joris, Magalie;Merlusca, Lavinia;Beaumont, Marie;Charbonnier, Amandine;Marolleau, Jean-Pierre;Gruson, Bérengère;
276 views DOI Abstract
39
Overall
Poor
31
15
30
40
34
50
0
0
0
0
0
Journament

Overall Quality Score

39.3/100

Tier: Poor

The Journament Overall Quality Score is a comprehensive metric that evaluates academic journals across multiple dimensions including engagement, accessibility, diversity, innovation, and community impact.

This score helps researchers, institutions, and publishers understand the holistic quality and impact of a journal beyond traditional metrics.

Engagement Score

30.6/100

Measures user interactions, views, citations, and community involvement with this journal's content.

Higher engagement scores indicate that the journal's content is actively being read, cited, and discussed within the academic community.

Accessibility Score

15.0/100

Evaluates how easily researchers can access journal content, including open access availability, ISSN registration, and indexing.

This metric considers factors such as paywalls, open access policies, and availability across different academic databases and search engines.

Diversity Score

30.0/100

Assesses geographic and institutional diversity of authors, editorial board composition, and topic breadth.

A diverse journal publishes work from various geographic regions, institutions, and covers a broad range of topics within its field.

Innovation Score

40.0/100

Evaluates research novelty, interdisciplinary work, and emerging topics based on AI analysis of article abstracts.

This score reflects how much the journal publishes cutting-edge research, explores new methodologies, and bridges different academic disciplines.

Community Impact Score

33.5/100

Measures scholarly contribution and real-world applications of published research.

This metric evaluates how the journal's research translates into practical applications, policy changes, and benefits to society beyond academia.

Timeliness Score

50.0/100

Evaluates recent publication activity, publication frequency, and currency of research topics.

Higher scores indicate consistent publishing schedules and timely coverage of current research trends.

Ethics & Transparency Score

0.0/100

Research Integrity (10% weight)

Assesses COPE standards compliance, ethical considerations in research, transparency in methodologies, and reproducibility practices.

This metric ensures the journal maintains high ethical standards and promotes transparent, trustworthy research.

Content Quality Score

0.0/100

Academic Rigor (20% weight) + Methodology Quality (12%)

Evaluates research methodology soundness, statistical rigor, theoretical framework strength, appropriateness of research methods, data quality, and clarity & readability.

This comprehensive metric ensures published research meets the highest academic standards.

Editorial Diversity Score

0.0/100

Author Diversity + Interdisciplinary Value (8%)

Measures geographic diversity of authors, institutional variety, editorial board composition, and cross-disciplinary connections.

Diverse editorial teams bring varied perspectives and reduce bias in academic publishing.

Publication Regularity Score

0.0/100

Assesses consistency of publication schedule, frequency stability, and predictable output patterns.

Regular publication schedules indicate reliable journal operations and consistent workflow management.

Geographic Reach Score

0.0/100

Evaluates international author representation, global readership distribution, and cross-border research collaboration.

Wide geographic reach indicates global impact and international recognition of the journal's research.